Brought to you by 
Abbott , Boehringer Ingelheim co-promote Flomax in US
05 Oct 2000
Executive Summary
Abbott Laboratories licensed US co-promotion rights to Boehringer Ingelheim Pharmaceuticals' Flomax (tamsulosin HCl), a treatment for benign prostatic hyperplasia (BPH). The drug was originally licensed from Yamanouchi in 1994, and BIP launched it in the US in late 1997.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott , Boehringer Ingelheim co-promote Flomax in US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice